

PRESS RELEASE

AtG Therapeutics Appoints Dr. Itziar Canamasas as New CEO to Drive Development of Cancer Metabolic Adaptation Inhibitors

Barcelona, March 20, 2023.- AtG Therapeutics, a pre-clinical stage biotech focused on stopping cancer metabolic adaptation, has announced the appointment of Itziar Canamasas, PhD as its new CEO.

Dr. Canamasas brings over 20 years of experience in the pharmaceutical industry, with expertise focused on global commercialisation, strategic life-cycle development, corporate strategy and country leadership. She was most recently the Head of Oncology EMEA at Bayer Pharmaceuticals.



Dr. Canamasas will lead the company's efforts to develop a pipeline of metabolic adaptation inhibitors and biomarkers to treat advanced cancer patients. *"I am thrilled to join AtG Therapeutics as CEO and lead the development of new treatment options. With AtG's innovative approach to stopping cancer metabolic adaptation, I am confident we can make significant strides in the field of oncology. I am honoured to be a part of this pioneering effort and look forward to making a difference in the lives of cancer patients,"* said **Dr. Canamasas**.

Dr. Canamasas also serves as a member of the board of directors at ALX Oncology and is the Organisational Development Director for the Ambassador Program at the Healthcare Businesswomen's Association (HBA).

Dr. Oriol Casanovas, Co-founder of AtG Therapeutics, commented, *"We are excited to have Itziar on board as CEO of AtG Therapeutics. Her extensive leadership experience and deep understanding of the pharmaceutical industry will be invaluable in driving the development of our pipeline of metabolic adaptation inhibitors. We are confident that under her leadership, the company will continue to grow and make significant impact in advancing the fight against cancer."*

Dr. Canamasas holds an MSc in Biology with Distinction from the University de Barcelona and a PhD in Cancer Genetics from the University of Mainz.

To learn more, visit <https://www.atgtx.com> and follow AtG Therapeutics on Twitter (@AtGTherapeutics) and LinkedIn.

Contact:

Dr. Gabriela Jiménez Valerio

Co-Founder & COO AtG Therapeutics S.L

gabriela@atgtx.com